The Lancet Infectious Diseases published Phase 2 results on Tuesday comparing different durations and doses of benznidazole (a standard of care for Chagas disease) alone or in combination with the antifungal fosravuconazole. According to a press release from the Drugs for Neglected Diseases initiative (DNDi), which led the study, a two-week benznidazole Chagas treatment had “similar efficacy and significantly fewer adverse effects” than the current standard eight-week regimen of the…
TB Alliance announced a collaboration Monday with ZebiAI to discover, develop and deliver “better, faster-acting and affordable” tuberculosis drugs using the Massachusetts-based company’s machine learning platform.
The project joins a trend in global health: artificial intelligence-driven discoveries in recent years include potential Chagas treatments identified through a Drugs for Neglected Diseases initiative collaboration and an MIT-discovered compound that kills a broad range of…
Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) announced $2.2 million in drug development investments on Tuesday.
Three of the four awards support new projects for Chagas disease and malaria. The remaining award goes toward an ongoing drug discovery project between Takeda and Geneva-based Medicines for Malaria Venture.
GHIT Fund’s portfolio now includes 53 ongoing projects with $217 million invested so far, according to the press release.
British researchers have developed a rapid diagnostic blood test that can detect and distinguish between the six strains of T. cruzi, the parasite that causes Chagas disease, Imperial College London announced last week.
Co-developed with the London School of Hygiene and Tropical Medicine and Kent-based nonprofit TroZonX17 (among others), the technology may lead to “widespread, inexpensive testing,” according to a TroZonX17 press release.
Science Translational Medicine published a study last week showing that higher doses of benznidazole on a modified regimen eliminated Chagas disease in three mouse models—findings that challenge PAHO’s and WHO’s standard of care for the disease.
In lieu of the standard twice-daily, two-month regimen, University of Georgia researchers gave the animals a weekly dose (up to five times higher than the comparable daily dose) for 30 weeks. The treatment cleared infection and eliminated…
The Drugs for Neglected Diseases initiative (DNDi) announced new funding this week from Spain’s la Caixa: a grant of $1.2 million over three years to identify “novel natural products” as potentially effective treatments for leishmaniasis and Chagas disease.
DNDi will share the funding with project coordinator Fundación MEDINA and Institut Pasteur Korea, the joint press release said.
Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) on Monday announced $13 million in drug and diagnostic investments.
Three of the seven awards will support new projects for malaria drug development and tests for schistosomiasis and Buruli ulcers. The remaining four will go toward ongoing projects to develop drugs for leishmaniasis, Chagas and soil-transmitted helminths and a rapid diagnostic for malaria.
GHIT Fund’s portfolio now includes 50 ongoing…
Novartis today announced a $2.2 billion “sustainability-linked bond” that the company says incentivizes its efforts to reach over 24 million people in low- and middle-income countries (LMICs) by 2025 through its Chagas, leprosy, malaria, and sickle cell disease access programs.
According to a Novartis press release, the Access to Medicine Foundation validated the bond’s targets, which also include a 200% increase in LMIC patients reached with unspecified “strategic innovative therapies…
Bayer announced on World Neglected Tropical Diseases Day (January 30) that it has submitted an application to the U.S. FDA for a new pediatric formulation of its Chagas drug nifurtimox that can be split into smaller pieces to adjust for body weight and dissolves quickly in water.
In the press release, the company also said it would improve access to the drug “through new applications for registrations in countries with a high disease burden” as part of a recently unveiled…
Brazil’s Oswaldo Cruz Foundation (Fiocruz) announced last week that it has signed a memorandum of understanding with Novartis to exchange academic and R&D “know-how” for neglected diseases such as leprosy, Chagas, malaria and sickle cell.
The press release did not disclose details; however, the two companies have previously worked together on leprosy R&D.